Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650302 | 0.90 | HPGD (0.50) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6752619 | 0.90 | HPGD (0.52) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2649744 | 0.84 | HPGD (0.60) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2648980 | 0.82 | HPGD (0.48) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2648975 | 0.82 | HPGD (0.48) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2653042 | 0.82 | FGFR1 (0.42) | HPGDKMT2ARIPK1RIPK3 | |
| SCHEMBL17420453 | 0.81 | AGXT (0.56) | ALDH1A1NPC1RAB9A | |
| SCHEMBL2655791 | 0.81 | ALDH1A1 (0.48) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2652431 | 0.80 | RIPK1 (0.42) | HPGDALDH1A1SMN1; SMN2KMT2ARIPK1 | |
| SCHEMBL6749284 | 0.80 | SIK1 (0.52) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | claimed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | claimed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | claimed |
| EP-0934281-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-11 | — | — | EP | claimed |
| WO-1998017651-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA-A RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1998-04-30 | — | — | WO | claimed |
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0934281-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017651-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA-A RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | HPGD 1806/4885ALDH1A1 192/4885SMN1; SMN2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.